Results 191 to 200 of about 6,017,324 (391)
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry +16 more
wiley +1 more source
Clinical Remarks on Hypertrophic Cirrhosis of the Liver with Bronzing of the Skin: Haemochromatosis [PDF]
William Osler
openalex +1 more source
Allyson L. Byrd, Y. Belkaid, J. Segre
semanticscholar +1 more source
Objective A leading cause of death among scleroderma (SSc) patients, interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M Padilla +13 more
wiley +1 more source
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis‐associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999‐2021. RA‐ILD patients were
Bryant R. England +9 more
wiley +1 more source
Radiation Pain Thresholds in Relation to Skin Temperatures [PDF]
J. W. Beattie, A. Woodmansey
openalex +1 more source
Objectives This study aims to develop hip morphology‐based radiographic hip osteoarthritis (RHOA) risk prediction models and investigates the added predictive value of hip morphology measurements and the generalizability to different populations. Methods We combined data from nine prospective cohort studies participating in the World COACH consortium ...
Myrthe A. van den Berg +26 more
wiley +1 more source
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan +7 more
wiley +1 more source

